| Downregulation of RCN1 inhibits esophageal squamous cell carcinoma progression and M2 macrophage polarization. | Downregulation of RCN1 inhibits esophageal squamous cell carcinoma progression and M2 macrophage polarization.
Guo H, Shu J, Hu G, Liu B, Li J, Sun J, Wang X, Liu H, Xiong S, Tang Y, Yin Y, Wang X., Free PMC Article | 06/3/2024 |
| RCN1 deficiency inhibits oral squamous cell carcinoma progression and THP-1 macrophage M2 polarization. | RCN1 deficiency inhibits oral squamous cell carcinoma progression and THP-1 macrophage M2 polarization.
Liu H, Guo H, Wu Y, Hu Q, Hu G, He H, Yin Y, Nan X, Lin G, Han J, Zhao R, Liu Y., Free PMC Article | 12/18/2023 |
| Downregulation of RCN1 promotes pyroptosis in acute myeloid leukemia cells. | Downregulation of RCN1 promotes pyroptosis in acute myeloid leukemia cells.
Deng S, Pan Y, An N, Chen F, Chen H, Wang H, Xu X, Liu R, Yang L, Wang X, Du X, Zhang Q., Free PMC Article | 12/15/2023 |
| Reticulocalbin-1 knockdown increases the sensitivity of cells to Adriamycin in nasopharyngeal carcinoma and promotes endoplasmic reticulum stress-induced cell apoptosis. | Reticulocalbin-1 knockdown increases the sensitivity of cells to Adriamycin in nasopharyngeal carcinoma and promotes endoplasmic reticulum stress-induced cell apoptosis.
Huang ZH, Qiao J, Feng YY, Qiu MT, Cheng T, Wang J, Zheng CF, Lv ZQ, Wang CH., Free PMC Article | 09/4/2021 |
| Salivary NUS1 and RCN1 Levels as Biomarkers for Oral Squamous Cell Carcinoma Diagnosis. | Salivary NUS1 and RCN1 Levels as Biomarkers for Oral Squamous Cell Carcinoma Diagnosis.
Ueda S, Hashimoto K, Miyabe S, Hasegawa S, Goto M, Shimizu D, Oh-Iwa I, Shimozato K, Nagao T, Nomoto S., Free PMC Article | 07/3/2021 |
| Our data indicate that RCN1 expression may have an vital role at promoting the occurrence of non-small cell lung cancer | Overexpression of RCN1 correlates with poor prognosis and progression in non-small cell lung cancer.
Chen X, Shao W, Huang H, Feng X, Yao S, Ke H. | 11/16/2019 |
| RCN1 may promote cell survival and serve as a useful target for cancer therapy. | Downregulation of reticulocalbin-1 differentially facilitates apoptosis and necroptosis in human prostate cancer cells.
Liu X, Zhang N, Wang D, Zhu D, Yuan Q, Zhang X, Qian L, Niu H, Lu Y, Ren G, Tian K, Yuan H., Free PMC Article | 04/21/2018 |
| irradiated tumor cells were observed to significantly up-regulate the expression of calcium-binding proteins CALM1, CALU, and RCN1, suggesting important roles for these mediators in promoting tumor cell survival during hypoxia | Irradiation of Epithelial Carcinoma Cells Upregulates Calcium-Binding Proteins That Promote Survival under Hypoxic Conditions.
Ren Y, Yeoh KW, Hao P, Kon OL, Sze SK. | 10/7/2017 |
| RCN1 expression was not statistically significantly different to healthy controls but was associated with disease activity score and could be used as a stratification biomarker for systemic sclerosis patients. | Circulating Reticulocalbin 1 and Reticulocalbin 3 in Systemic Sclerosis Patients: Results of a Case Control Study.
Bălănescu P, Lădaru A, Bălănescu E, Pompilian V, Gologanu D, Caraiola S, Băicuş C, Dan GA. | 09/10/2016 |
| reticulocalbin-1 plays a key role in the development of doxorubicin-associated resistance | Identification of up- and down-regulated proteins in doxorubicin-resistant uterine cancer cells: reticulocalbin-1 plays a key role in the development of doxorubicin-associated resistance.
May EW, Lin ST, Lin CC, Chang JF, Hung E, Lo YW, Lin LH, Hu RY, Feng CL, Lin DY, Wu SB, Lee WC, Lyu KW, Chou HC, Chan HL. | 08/15/2015 |
| Ca(2+) binding caused an increase in the alpha-helix content of human RCN1. On the other hand, RCN1 did not change the structure with Mg. | Calcium-dependent structural changes in human reticulocalbin-1.
Suzuki N, Ban S, Itoh E, Chen S, Imai FL, Sawano Y, Miyakawa T, Tanokura M, Yonezawa N. | 05/23/2015 |
| a promising role of RCN1 as a possible marker in Renal cell carcinoma | Proteomic identification of Reticulocalbin 1 as potential tumor marker in renal cell carcinoma.
Giribaldi G, Barbero G, Mandili G, Daniele L, Khadjavi A, Notarpietro A, Ulliers D, Prato M, Minero VG, Battaglia A, Allasia M, Bosio A, Sapino A, Gontero P, Frea B, Fontana D, Destefanis P. | 12/6/2014 |
| reticulocalbin-1 may be an important molecule in understanding lymphatic endothelial cells in tumors function and control of lymphatic metastasis. | Limited expression of reticulocalbin-1 in lymphatic endothelial cells in lung tumor but not in normal lung.
Yoshida Y, Yamashita T, Nagano K, Imai S, Nabeshi H, Yoshikawa T, Yoshioka Y, Abe Y, Kamada H, Tsutsumi Y, Tsunoda S. | 04/16/2011 |
| Increased RCN1 is associated with systemic sclerosis and nephrogenic systemic fibrosis. | Proteomic analysis identification of a pattern of shared alterations in the secretome of dermal fibroblasts from systemic sclerosis and nephrogenic systemic fibrosis.
Del Galdo F, Shaw MA, Jimenez SA., Free PMC Article | 03/12/2011 |
| deletion of Rcn1 directly or indirectly contributes to the eye phenotype in Pax6 contiguous gene deletions | Analysis of Pax6 contiguous gene deletions in the mouse, Mus musculus, identifies regions distinct from Pax6 responsible for extreme small-eye and belly-spotting phenotypes.
Favor J, Bradley A, Conte N, Janik D, Pretsch W, Reitmeir P, Rosemann M, Schmahl W, Wienberg J, Zaus I., Free PMC Article | 02/8/2010 |
| Data show that calumenin in the presence of calcium binds specifically to thrombospondin-1, but closely-related reticulocalbin does not form a similar complex. | Calumenin but not reticulocalbin forms a Ca2+-dependent complex with thrombospondin-1. A potential role in haemostasis and thrombosis.
Hansen GA, Vorum H, Jacobsen C, Honoré B. | 01/21/2010 |
| RCN1 also is expressed on the cell surface of several endothelial cell lines, including human dermal microvascular endothelial cells (HDMVECs), bone marrow endothelial cells (BMEC), and transformed human bone marrow endothelial cells (TrHBMEC). | Novel surface expression of reticulocalbin 1 on bone endothelial cells and human prostate cancer cells is regulated by TNF-alpha.
Cooper CR, Graves B, Pruitt F, Chaib H, Lynch JE, Cox AK, Sequeria L, van Golen KL, Evans A, Czymmek K, Bullard RS, Donald CD, Sol-Church K, Gendernalik JD, Weksler B, Farach-Carson MC, Macoska JA, Sikes RA, Pienta KJ. | 01/21/2010 |